Association of sociodemographic, clinical andlaboratory parameters with the time taken to seek careand patient outcomes in patients with febrile neutropenia
DOI:
https://doi.org/10.11606/issn.2176-7262.rmrp.2026.218393Palabras clave:
Febrile neutropenia, Oncohematology, Chemotherapy, Antibiotic therapyResumen
Febrile neutropenia (FN) is a frequent clinical emergency in oncohematological patients. Currently, one of the main obstacles associated with patient management is the delay in administering antibiotic therapy, and in this context, the most recent guidelines point to the importance of carrying out
rapid screening and risk stratification using validated criteria. However, in practice, alarming rates of morbidity, mortality, and expenses related to the disease persist. Given this scenario, the present study aimed to evaluate the impact of the time to start antibiotic therapy on the clinical outcome in oncohematological patients admitted with FN. Through the analysis of medical records from the year 2018 and prospective study through clinical interviews, the aim was to outline the medical care profile of oncohematological patients with FN from pre-hospital care and seek possible correlations between the medical profile of the patient and the time taken to seek care, the approach adopted and the outcome. Concerning the variables possibly predictive of hospital discharge or death, there was no statistically significant difference between the groups about the variables sex, age, education,origin, hematological parameters, use of granulocyte colony-stimulating factor, number of antibiotics or association with antifungals and the result of urine culture. However, there was a significantly higher number of deaths in non-white patients, with peripheral oxygen desaturation, the need to stay in an intensive care unit, and the presence of gram-negative bacteria. The analysis of the influence of clinical and laboratory factors on the waiting time to seek care showed that sex, skin color, age group, origin, education level, blood pressure, heart rate, oxygen saturation, neutropenia, and days of hospitalization were not associated with waiting time to seek medical care. Regarding clinical and laboratory parameters, the longer waiting time was associated with the need for intensive therapy and the type of cancer, being higher in patients with lymphoma. The results obtained contributed to a better understanding of the diagnostic and therapeutic processes involved in FN, clarifying the most important causes of delay in treatment, which will allow the planning of actions that have a positive impact on the care of these patients.
Descargas
Referencias
1. Pracchia LF, Costa SF. Febril e neutropenia. Clinical Emergencies. 8th ed., Barueri/SP: Manole; 2013, p. 912-20.
2. Cerqueira JP, Fonseca TS, Santos MT, Fonseca GL, Sousa MR, Warol PH, et al. Na analysis of the characteristics of febrile neutropenia: a literature review. REAS; 2022. 15 (3): 9869.
3. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis; 2011. 52(4): 56-93.
4. Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. J Clin Oncol; 2018. 36 (14). 1443-53.
5. Dale DC. How I diagnose and treat neutropenia. Curr Opin Hematol ; 2016. 23(1):1-4.
6. Bodey GP, Buckey M, Sathe YS, Freireich EJ. Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia. Annals of Internal Medicine; 1996. 64(2), 328–40.
7. Hersh EM, Boddey GP, Nies BA, Freireich EJ. Causes of Death in Acute Leukemia. JAMA; 1965. 193 (2):105-9.
8. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, Morbidity, and Cost Associated with Febrile Neutropenia in Adult Cancer Patients. Cancer; 2006. 106(10):2258-66.
9. Keng MK, Sekeres MA. Febrile Neutropenia in Hematologic Malignancies. Curr Hematol Malig Rep; 2013. 8(4): 370-8.
10. Guarana M, Nucci M, Nauér AS. Shock and Early 1 Death in Hematologic Patients with Febrile Neutropenia. Antimicrob Agents Chemother; 2019. 63(11): 1-25.
11. Legrand M, Max A, Peigne V, Mariotte E, Canet E, Debrumetz A. Survival in neutropenic patients with severe sepsis or septic shock. Crit Care Med; 2012. 40 (1): 43-9.
12. O’Horo JC, Marcelin JR, Abu Saleh OM, Barwise AK, Odean PM, Rivera CG, Tande AJ, et al. Standardizing Febrile Neutropenia Management: Antimicrobial Stewardship in the Hematologic Malignancy Population. J Oncol Pract; 2019. 15 (9): 1-6.
13. Peseski AM, McClean M, Green SD, Beeler C, Konig H. Management of fever and neutropenia in the adult patient with acute myeloid leukemia. Expert Rev Anti Infect Ther; 2020. 19 (3): 359-78.
14. Baugh CW. Near-universal hospitalization of US emergency department patients with cancer and febrile neutropenia. PLoS One; 2019. 14 (5): 1-7.
15. Naurois J, Basso IN, Gill MJ, Marti FM, Cullen MH, Roila F. Management of febrile neutropenia: ESMO Clinical Practice Guidelines On behalf of the ESMO Guidelines Working Group. Ann Oncol; 2010. 21 (5): 1-5.
16. Perron T, Emara M, Ahmed S. Time to antibiotics and outcomes in cancer patients with febrile neutropenia. BMC Health Serv Res; 2014. 14: 1-7.
17. Rosa RG, Goldani LZ. Cohort study of the impact of time to antibiotic administration on mortality in patients with febrile neutropenia. Antimicrob Agents Chemother; 2014. 58 (7): 3799-803.
18. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Onco; 2000. 18(16): 3038-3051.
19. Tai E. Cost of Cancer-Related Neutropenia or Fever Hospitalizations, United States, 2012.J Oncol Pract; 2017. 13 (6): 386-97.
20. Daniels LM, Durani U, Barreto JN, O’Horo JC, Siddiqui MA, Park JG, Tosh PK. Impact of time on antibiotics on hospital stay, intensive care unit admission, and mortality in febrile neutropenia. Support Care Cancer; 2019. 27 (11): 4171-7.
21. Newburger PE, Dale DC. Evaluation and Management of Patients With Isolated Neutropenia. Semin Hematol; 2013. 50 (3):198-206.
22. IBGE – Brazilian Institute of Geography and Statistics. 2017 Brazilian Census.. Rio de Janeiro: IBGE, 2018.
23. Barbosa SF, Costa CA, Ferreira LS, Almeida DS, Azevedo TC, Lemos JA, et al. Epidemiological aspects of cases of leukaemia and lymphomas in young people and adults treated at a câncer referencial hospital in Belém , state of Pará, Amazonia, Brazil. Pan-Amaz Saude; 2015. 6 (3): 43-50.
24. IBGE – Brazilian Institute of Geography and Statistics. 2019 Brazilian Census. Rio de Janeiro: IBGE, 2020.
25. Logan C, Koura D, Taplitz R. Updates on infection risk and management in acute leukemia. Hematology Am Soc Hematol Educ Program; 2020. 2020 (1): 135-9.
26. Martinez AR, Pascual IP, Rubio EM. Protocol for the diagnosis and treatment of febrile neutropenia; 2018. 12 (55): 3272-6.
27. Klastersky J. Management of Fever in Neutropenic Patients with Different Risks of Complications. Clin Infect Dis; 2004. 39 (1): 32-7.
28. Ali AM, Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen. Cancer Med; 2017. 6 (12): 1-8.
29. Parodi RL, Lagrutta M, Tortolo M, Navall E, Rodríguez MS, Sasia GF, et al. A multicenter prospective study of 515 febrile neutropenia episodes in Argentina during a 5-year period. PLoS One; 2019. 14 (10): 1- 15.
30. Schmidt- Hieber M, Teschner D, Maschmeyer G, Schalk E. Management of febrile neutropenia in special consideration of the role of antimicrobial de-escalation. Expert Rev Anti Infect Ther; 2019. 17 (12): 1-47.
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2026 Ítala Alvarenga Gomes Oliveira, Gabriela Rodrigues Andrade, Gilberto de Araújo Pereira, Fernanda Bernadelli De Vito, Helio Moraes-Souza

Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Cómo citar
Datos de los fondos
-
Fundação de Amparo à Pesquisa do Estado de Minas Gerais
Números de la subvención 001



